Prostatype Genomics appoints Anders Koch as new CFO

Anders Koch has been appointed as the new CFO for Prostatype Genomics and takes up the position with immediate effect. Anders' extensive experience in streamlining and optimizing operations during growth on an international level will be a great asset for Prostatype Genomics.

Anders Koch has over 25 years of experience from positions in finance and leadership, most recently from an interim assignment at Goodbye Kansas Group AB (publ), also listed on Nasdaq First North.

Prostatype Genomics CEO Fredrik Persson says: "Anders' competence and experience in structuring and streamlining operations in changing development phases is exactly what Prostatype Genomics needs right now and we are happy that he has been able to join us in a consulting role. Anders' strategic ability will contribute to both more efficient processes and to achieve our financial goals, while the appointment is in line with the company's communicated efficiency program."

"Prostatype Genomics is an exciting company with a fantastic product that fills a clear clinical need, and I believe and that my experience in working with, and focusing on, value-creating actions and processes can help Prostatype Genomics in the company's continued exciting journey moving forward," says Anders Koch.

Anders Koch succeeds Michael af Winklerfelt, who remains in the company during a handover period.

For questions, please contact CEO Fredrik Persson at email: fredrik.persson@prostatypegenomics.com.

Certified Adviser:
Erik Penser Bank AB, Box 7405, 103 91 Stockholm,
Telephone: +46 (0)8-463 80 00
e-mail: certifiedadviser@penser.se

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.